Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M M Borner

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Neuroscience Letters|April 25, 1994
Internucleosomal DNA fragmentation in gerbil hippocampus following forebrain ischemiaY Sei, K J Von Lubitz, A S Basile, et al.
Oncology|January 11, 2001
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancerD P Rauch, C A Maurer, S Aebi, et al.
Lung Cancer (Amsterdam, Netherlands)|September 12, 2001
Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumoursM Gugger, A Kappeler, S Vonlanthen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 1999
Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK)A D Roth, R Herrmann, R Morant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trialA D Roth, R Maibach, N Fazio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)M M Borner, M Castiglione, M Bacchi, et al.
British Journal of Cancer|March 10, 1999
Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancerM M Borner, P Brousset, B Pfanner-Meyer, et al.
Oncogene|December 5, 1998
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpressionS Vonlanthen, J Heighway, M P Tschan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2005
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicityM M Borner, J Bernhard, D Dietrich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2000
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)A D Roth, R Maibach, G Martinelli, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Neuroscience Letters|April 25, 1994
Internucleosomal DNA fragmentation in gerbil hippocampus following forebrain ischemiaY Sei, K J Von Lubitz, A S Basile, et al.
Oncology|January 11, 2001
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancerD P Rauch, C A Maurer, S Aebi, et al.
Lung Cancer (Amsterdam, Netherlands)|September 12, 2001
Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumoursM Gugger, A Kappeler, S Vonlanthen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 1999
Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK)A D Roth, R Herrmann, R Morant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trialA D Roth, R Maibach, N Fazio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)M M Borner, M Castiglione, M Bacchi, et al.
British Journal of Cancer|March 10, 1999
Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancerM M Borner, P Brousset, B Pfanner-Meyer, et al.
Oncogene|December 5, 1998
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpressionS Vonlanthen, J Heighway, M P Tschan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2005
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicityM M Borner, J Bernhard, D Dietrich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2000
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)A D Roth, R Maibach, G Martinelli, et al.
Pageof 4